SurgePays (SURG) Cash & Equivalents (2010 - 2026)

SurgePays has disclosed Cash & Equivalents across 17 years of filings, most recently posting $2.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 55.24% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 55.24% YoY), while the FY2025 annual figure was $1.7 million, down 86.46% from the prior year.
• Cash & Equivalents climbed to $2.4 million in Q1 2026, from $1.7 million in the prior quarter.
• Over the last five years, Cash & Equivalents for SURG reached as high as $42.9 million in Q1 2024 and fell as low as $1.7 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $7.9 million (2022), against an average of $11.3 million.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 1414.29% — and 2025, when it slumped 88.54%.
• A 5-year view of Cash & Equivalents shows it stood at $7.0 million in 2022, then soared by 107.83% to $14.6 million in 2023, then dropped by 12.53% to $12.8 million in 2024, then plunged by 86.46% to $1.7 million in 2025, then jumped by 39.55% to $2.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $2.4 million, $1.7 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.